BusinessAvid Bioservices Provides Update on Ongoing Expansion of Process Development Capabilities and Laboratory InfrastructureBy Nasdaq OMXApr 24, 2018, 12:05 PM UTC
BusinessAvid Bioservices to Participate at Upcoming CDMO Industry ConferencesBy Nasdaq OMXMar 13, 2018, 12:05 PM UTC
BusinessAvid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXMar 7, 2018, 9:06 PM UTC
BusinessAvid Bioservices to Present at the 30th Annual ROTH ConferenceBy Nasdaq OMXMar 6, 2018, 1:05 PM UTC
BusinessAvid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018By Nasdaq OMXMar 5, 2018, 1:05 PM UTC
BusinessAvid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer’s Disease CandidateBy Nasdaq OMXMar 1, 2018, 1:05 PM UTC
BusinessAvid Bioservices Announces Resignation of Chief Financial OfficerBy Nasdaq OMXFeb 26, 2018, 1:05 PM UTC
BusinessAvid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant SciencesBy Nasdaq OMXFeb 21, 2018, 1:05 PM UTC
